Pluristem Therapeutics is a clinical-stage biotherapy company using placental cells and an advanced 3D manufacturing platform to develop cell therapies for conditions that include inflammation, ischemia, muscle trauma, hematological disorders, or exposure to radiation. Their two lead cell products are entering late-stage clinical trials. Based in Haifa, Israel, Pluristem’s propriety bioreactor technology provides full-scale cell manufacturing capabilities that allow it to expand trillions of cells and create a commercial-grade product.
In the video below, Karine Kleinhaus, MD, MPH, Divisional Vice President, North America at Pluristem Therapeutics, discusses the company’s 3D manufacturing technology, as well as the strategic advantages of its placental-derived PLX cells, which are “off-the-shelf” products that do not need genetic or tissue matching prior to administration and could be delivered in almost any clinical setting. She also discusses the company’s current PLX-PAD clinical trials and recent non-human primate study of PLX-R18 in Acute Radiation Syndrome (ARS).
To learn more, watch Pluristem Therapeutics’ Cell and Gene Investor Day presentation with Dr. Karine Kleinhaus and Edward Tenthoff, Managing Director and Senior Research Analyst at Piper Jaffray.
For more information, view our recent interview with Yaky Yanay, President and Co-CEO of Pluristem Therapeutics.
